<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="307">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05200598</url>
  </required_header>
  <id_info>
    <org_study_id>22-21</org_study_id>
    <nct_id>NCT05200598</nct_id>
  </id_info>
  <brief_title>Cardiovascular Risk Predictors in Patients With Psoriasis</brief_title>
  <official_title>Cardiovascular Risk Predictors in Patients With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are planning to find the right modification of traditionally used risk&#xD;
      scores (PASI, DLQI) in patients with psoriasis of different severity to guide the treatment&#xD;
      that could potentially extend life, improve cardiovascular outcomes and quality of life in&#xD;
      patients with psoriasis and cardiovascular risk factors in a prospective observational study.&#xD;
      The traditionally excluded groups of older patients with diabetes mellitus, decreased kidney&#xD;
      function and those with potentially worse prognosis are going to be included in the study. As&#xD;
      it's known, the number of those patients is on the rise each year and require a close&#xD;
      attention of multidisciplinary teams.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SCORE2-OP risk (Systematic COronary Risk Evaluation2- Older Person)</measure>
    <time_frame>1 year</time_frame>
    <description>Increased cardiovascular risk over the follow-up period (from low to very high)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Overall mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiovascular mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of psoriasis (PASI)</measure>
    <time_frame>1 year</time_frame>
    <description>Progression of severity of psoriasis according to PASI (The Psoriasis Area and Severity Index - 0 to 4, none to very severe) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (DLQI score)</measure>
    <time_frame>1 year</time_frame>
    <description>Impact on quality of life by DLQI (Dermatology Life Quality Index - 0 to 30, no to extremely large impact) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to cardiovascular reasons</measure>
    <time_frame>1 year</time_frame>
    <description>Hospitalization due to cardiovascular reasons</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Psoriasis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Mild psoriasis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate psoriasis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe psoriasis not receiving systemic therapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe psoriasis receiving systemic therapy with genetic-engineering biological drugs</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without psoriasis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Considering the different severity of psoriasis, it is possible to divide patients with&#xD;
        psoriasis into several subgroups: patients with mild psoriasis; patients with moderate&#xD;
        psoriasis; patients with severe psoriasis who are not receiving systemic therapy; patients&#xD;
        with severe psoriasis receiving systemic therapy with genetic-engineering biological drugs;&#xD;
        patients with psoriatic arthritis receiving genetic-engineering biological drugs.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18 years&#xD;
&#xD;
          -  Written informed consent of the patient to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Very high cardiovascular risk&#xD;
&#xD;
          -  Life-threatening, independently influencing prognosis and disabling diseases,&#xD;
&#xD;
          -  Mental disorders that do not allow to give informed consent or answer questions&#xD;
             adequately&#xD;
&#xD;
          -  Refuse of the patient to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Mironova, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sechenov University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga Kuzmina, MD</last_name>
    <phone>+79260497300</phone>
    <email>oakuzzmina@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anfisa Lepekhova, MD, PhD</last_name>
    <phone>+79035433074</phone>
    <email>anfisa.lepehova@yandex.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinical Hospital #2</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Kuzmina, MD</last_name>
      <phone>+79260497300</phone>
      <email>oakuzzmina@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>January 1, 2022</study_first_submitted>
  <study_first_submitted_qc>January 19, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2022</study_first_posted>
  <last_update_submitted>January 19, 2022</last_update_submitted>
  <last_update_submitted_qc>January 19, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.M. Sechenov First Moscow State Medical University</investigator_affiliation>
    <investigator_full_name>Olga Mironova</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

